Outlook Therapeutics, Inc.
(NASDAQ: OTLK)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

1.990

-0.070 (-3.40%)
Range 1.975 - 2.090   (5.82%)
Open 2.080
Previous Close 2.060
Bid Price 1.500
Bid Volume 29
Ask Price 1.510
Ask Volume 13
Volume 791,926
Value -
Remark
Delayed prices. Updated at 06 Dec 2025 00:06.
Data powered by
View All Events

Loading Chart...

Please login to view stock data and analysis